**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 27226**

**Manuscript Type: Systematic Review**

**Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease**

Arulanandan A *et al*. Balloon assisted enteroscopy in CD

Ahilan Arulanandan, Parambir S Dulai, Siddharth Singh, William J Sandborn, Denise Kalmaz

**Ahilan Arulanandan, Parambir S Dulai, Siddharth Singh, William J Sandborn, Denise Kalmaz,** Division of Gastroenterology, University of California San Diego, San Diego, CA 92037, United States

**Author contributions:** Arulanandan A, Dulai PS and Kalmaz D created the study and design; Arulanandan A and Dulai PS acquired the data; Arulanandan A, Dulai PS and Singh S analyzed data, interpreted data, and drafted the manuscript; Dulai PS, Singh S, Sandborn WJ and Kalmaz D made critical revisions to manuscript and supervised study.

**supported by** training grant through the National Institute of Diabetes and Digestive and Kidney Diseases, No. 5T32DK007202 (to Dulai PS).

**Conflict-of-interest statement:** All authors have no relevant conflicts of interest.

**Data sharing statement:** There are no additional data.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**correspondence to**: **Ahilan Arulanandan, MD,** Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92037, United States. ahilanarul@gmail.com

**Telephone:** +1-858-6575278

**Fax:** +1-858-6575022

**Received:** May 18, 2016

**Peer-review started:** May 18, 2016

**First decision:** June 20, 2016

**Revised:** July 1, 2016

**Accepted:** August 1, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM**: To determine the overall and comparative risk of procedure related perforation of balloon assisted enteroscopy (BAE) in Crohn’s disease (CD).

**METHODS**: Systematic review (PROSPERO #CRD42015016381) of studies reporting on CD patients undergoing BAE. Seventy-three studies reporting on 1,812 patients undergoing 2340 BAEs were included. Primary outcome of interest was the overall and comparative risk of procedure related perforation of diagnostic BAE in CD. Secondary outcomes of interest were risk of procedure related perforation of diagnostic double balloon enteroscopy (DBE), risk of procedure related perforation of therapeutic BAE, efficacy of stricture dilation, and clinical utility of endoscopically assessing small bowel disease activity.

**RESULTS**: Per procedure perforation rate of diagnostic BAE in CD was 0.15% (95%CI: 0.05-0.45), which was similar to diagnostic BAE for all indications (0.11%; IRR = 1.41, 95%CI: 0.28 – 4.50). Per procedure perforation rate of diagnostic DBE in CD was 0.12% (95%CI: 0.03-0.44), which was similar to diagnostic DBE for all indications (0.22%; IRR = 0.54, 95%CI: 0.06–0.24). Per procedure perforation rate of therapeutic BAE in CD was 1.74% (95%CI: 0.85-3.55). 86% of therapeutic perforations were secondary to stricture dilation. Dilation was attempted in 207 patients and 30% required surgery during median follow-up of 18 months. When diagnostic BAE assessed small bowel disease activity, changes in medical therapy resulted in endoscopic improvement in 77% of patients.

**CONCLUSION:** Diagnostic BAE in CD has a similar rate of perforation as diagnostic BAE for all indications and can be safely performed in assessment of mucosal healing.

**Key words:** Crohn’s; Balloon; Enteroscopy; Safety; Perforation; Stricture

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Crohn’s disease (CD) affects the small bowel in up to 60% of patients, but evaluation of small bowel disease is often difficult. Balloon assisted enteroscopy can evaluate the small bowel but its safety and diagnostic utility is not established. This systematic review includes 73 studies reporting on 1812 patients undergoing 2340 procedures to evaluate its safety and possible utility. We found that diagnostic balloon assisted enteroscopy in CD had a similar rate of perforation as diagnostic balloon assisted enteroscopy for all indications, suggesting balloon assisted enteroscopy is a safe method for small bowel evaluation in CD.

Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Crohn’s disease (CD) is a debilitating chronic inflammatory bowel disease (IBD), which if left untreated, leads to penetrating complications (strictures, fistulae, abscesses)[1-3]. Frequent disease activity assessment with the intent of adjusting therapy has been demonstrated to significantly reduce the risk of disease related complications[4-10]. Small bowel involvement in CD is reported to occur in up to 60% of patients, with nearly 30% of patients having isolated small bowel disease[11-13]. Conventional upper and lower endoscopy, however, are limited in their ability to assess small bowel disease activity[14-18], and clinical or biochemical markers of disease activity infrequently correlate with small bowel mucosal inflammation[19]. The presence of inflammation cannot be reliably excluded by radiological imaging alone[20], and video capsule endoscopy (VCE) carries a risk for capsule retention in structuring or penetrating disease and it lacks therapeutic capability[21-24].

Balloon assisted enteroscopy (BAE) offers the advantage of providing both diagnostic (mucosal biopsies) and therapeutic (stricture dilation) potential, but its use in CD is currently limited to symptomatic patients with negative ileocolonoscopy, VCE, and/or cross sectional imaging, and the feasibility and diagnostic utility of routine BAE in clinical practice for CD is yet to be established[20, 25-29]. Therefore, we performed a systematic review of the literature to quantify the safety and therapeutic utility of this endoscopic technique. We anticipate these data will help to better characterize the growing importance of BAE in CD.

**MATERIALS AND METHODS**

***Data sources and search strategy***

The following databases were searched in October 2015: MEDLINE (PubMed, January 1946 to October 3, 2015); Cochrane Central Register of Controlled Trials (Wiley, 2015); and Embase (Embase.com, January 1974 to October 3, 2015). The search included indexed terms and text words to capture the following concepts: Crohn’s disease and balloon enteroscopy. There were no language or study design restrictions. The search strategy was adjusted for the syntax appropriate for each database. The reference lists of included articles and review articles were examined for additional relevant studies. The full search strategy, a priori, is available at the international prospective register of systematic reviews (PROSPERO #CRD42015016381).

***Study selection and extraction***

Studies were included for analysis if they met the following inclusion criteria: Randomized controlled trials, cohort studies, published meeting abstracts, or case series of 5 or more consecutive patients with CD, undergoing BAE for diagnostic or therapeutic purposes. Review articles and studies with fewer than 5 patients with CD were excluded. Studies with insufficient data for adverse outcomes and follow-up were excluded only after attempting to contact the primary author(s). The included population was patients of all ages with CD undergoing BAE for diagnostic and/or therapeutic purposes with clearly reported adverse outcomes. Comparative studies to assess diagnostic performance, therapeutic utility, and safety of BAE were included.

Two reviewers (A.A. and P.S.D.) independently evaluated each of the articles for eligibility. Inclusion decisions for each article were made independently based on the eligibility criteria, with disagreements being resolved by a third reviewer (D.K.) and consensus. A reviewer (A.A.) contacted the primary author(s) as required to obtain any necessary missing data from the original publications and because no language restrictions were applied, publications were translated into English as required. The reviewers followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards for systematic review.

***Outcomes***

Our primary outcome of interest was the safety of diagnostic BAE [single (SBE) or double (DBE) balloon enteroscopy) in CD, for which we calculated per procedure perforation rate and compared that to per procedure perforation rate when using diagnostic BAE for all indications. The expected rate of perforation when utilizing diagnostic BAE for all indications was derived from a Japanese database of 29068 patients[30].

Secondary outcome of interest was the safety of diagnostic DBE in CD, for which we calculated per procedure perforation rate and compared that to per procedure perforation rate when using diagnostic DBE for all indications. The expected rate of perforation when utilizing diagnostic DBE for all indications was derived from a systematic review of 9047 DBEs[31]. Other outcomes of interest were risk of procedure related perforation of therapeutic BAE, efficacy of stricture dilation, and clinical utility of endoscopically assessing small bowel disease activity.

***Statistical analysis***

We used the random-effects model described by DerSimonian and Laird to calculate pooled rates (and 95%CI) of perforation with BAE, stratified by indication (diagnostic versus therapeutic)[32]. Due to lack of consistent reporting in multiple studies, we did not perform a quantitative meta-analysis of factors associated with perforation, but rather discussed them qualitatively. The STATA “incidence ratio (IR)” command (version 10.0; STATA, College Station, TX) was used to make comparisons for perforation rates, and the relative rates for perforation were calculated as incidence rate ratios (IRRs).

**RESULTS**

***Patient and study characteristics***

Of the 638 studies identified, 73 studies reporting on 1,812 CD patients undergoing 2,340 BAE procedures (DBE: *n =* 2,027, SBE: *n =* 187, BAE not-specified: *n =* 126) were included in the final analysis[28,33-104] (Figure 1, Tables 1 and 2). The majority of studies involved international institutions (85%)[28,33,34,36-40, 42-47,51-56,58,61-78,80-93,96,97,99-105], reporting retrospectively (74%)[34,35,37-43,47-51,53-57,59,60,62,63,65,67-69,71-73,75-85,87-91,93-96,99,101,102,104], on their experience with BAE. Of the 1812 patients included in the analysis, 597 (33%) were newly diagnosed with CD and 1215 (67%) had a known diagnosis of CD prior to undergoing BAE. Among the patients with known CD where the indication for the procedure was clearly documented, BAE was performed primarily for monitoring of disease activity (61%), known strictures (16%), or small bowel obstruction (4%). 1938 BAE (83%) were diagnostic and 402 BAE (17%) were therapeutic procedures.

The 3 prospective randomized controlled trials identified in our search reported on a total of 37 CD patients[44,52,61]. Two of these studies compared DBE to SBE and found DBE to have comparable[52] or superior efficacy and diagnostic yield[44], while the other suggested that fluoroscopy increases insertion depth[61]. The largest prospective cohort study included 193 patients from 62 endoscopic centers in Germany over a 2-year span and had no perforations in CD patients[64].

***Safety of BAE***

The rate of perforation with diagnostic BAE in CD (1.5 per 1000 procedures) was similar to that reported when utilizing diagnostic BAE for all indications (1.1 per 1000 procedures, IRR = 1.41, 95%CI: 0.28–4.50). The rate of perforation with diagnostic DBE in CD (1.2 per 1000 procedures) was similar to that reported when utilizing diagnostic DBE for all indications (2.2 per 1000 procedures, IRR = 0.54, 95%CI: 0.06–2.24). The rate of perforation with therapeutic BAE in CD was 1.74% (Tables 3 and 4).

Among 1812 patients who underwent a total of 2340 procedures, there were 8 reported perforations with DBE (per procedure 0.39%, 95%CI: 0.12–0.66, per patient 0.53%, 95%CI: 0.16–0.90)[33-35,48,49,85,91,94,96], 1 reported perforation with SBE (per procedure and per patient 0.53%, 95%CI: 0.0–1.57)[96], and 1 perforation with BAE not otherwise specified. Of the 8 DBE perforations, 5 were during dilation of de novo CD strictures and the other 3 were during diagnostic evaluations of an adhesion site, an anastomosis stricture, and a site that was not specified. The 1 SBE perforation was during dilation of a de novo CD stricture site. This equated to an overall per procedure and per patient perforation rate of 0.43% (95%CI: 0.16–0.67) and 0.55% (95%CI: 0.21–0.89), respectively, for BAE in CD including both diagnostic and therapeutic procedures[94]. There was minimal heterogeneity among studies (*I*2 = 0%).

***Follow-up and impact of BAE on medical and surgical management***

Follow-up after BAE was reported in 407 patients with a median follow-up period of 18 mo (range 10–70)[28,33-40,85,86,88,91] (Figure 2). Stricture dilation was performed in 171 patients, resulting in 5 perforations (all at de novo CD stricture sites) and 166 technically successful dilations. Dilation was not attempted in 36 patients due to: inability to insert scope up to stricture site (*n =* 8), inability to maintain guide wire or through-the-scope balloon at correct position of the stricture (*n =* 5), stricture length or severe angulation (*n =* 4), severe inflammation (*n =* 6), the presence of intra-abdominal adhesions that prohibited advancement of the DBE (*n =* 2), a perforation during overtube advancement at an anastomotic site (*n =* 1), and/or non-obstructing or severely ulcerated strictures (*n =* 10). During follow-up, of the 166 patients where stricture dilation was technically successful, 72 (43%) required repeat stricture dilation and 42 (25%) patients required surgery for persistent symptoms.

Of the remaining 200 patients, 173 had clearly reported outcomes regarding changes in medical therapy and treatment response[28,36,86,88,91]. Based on BAE findings, 139 (80%) patients either initiated therapy with an immunomodulator (azathioprine or methotrexate, *n =* 83), initiated therapy with an anti-tumor necrosis factor agent (*n =* 52), or they were switched from one anti-tumor necrosis factor agent to another (*n =* 4). Seven (4%) patients required surgery, and the remaining either refused a step-up in medical therapy (*n =* 9, 5%) or they had no change in medical therapy needed (*n =* 18, 10%). Of the 139 patients where a change in medical therapy was performed, 92 (66%) achieved clinical remission at the first follow-up (as defined by the cd activity index)[28,36,86,88]. Repeat BAE was performed in 133 patients with a majority achieving endoscopic improvement in disease activity or complete healing of mucosal lesions (62%)[28,36,86,88]. A third follow-up BAE was performed in 113 patients, and rates of complete or nearly-complete mucosal healing improved from 29% (*n =* 33) to 43% (*n =* 57) with changes in therapy based on BAE results[86].

**DISCUSSION**

In our systematic review of 1812 CD patients undergoing 2340 BAE, the rate of perforation with diagnostic BAE in CD was similar to that seen when utilizing diagnostic BAE for other indications. The rate of perforation with diagnostic DBE in CD was also similar to that seen when utilizing diagnostic DBE for other indications. Additionally, findings from diagnostic BAE in conjunction with changes in medical therapy resulted in improved clinical and endoscopic disease activity in a majority of patients. Diagnostic BAE demonstrated a meaningful change in clinical care with a similar safety profile in CD compared to other indications.

Therapeutic BAE also exhibited significant clinical utility as approximately 70% of patients in our study avoided surgery after stricture dilation, albeit with higher rates of perforation. This increased risk of perforation with stricture dilation in CD[106] must be weighed against the therapeutic benefits achieved. Efforts need to focus on risk stratification of small bowel strictures to determine which patients may be more suitable for small bowel resection as compared to endoscopic dilation. Prior studies have demonstrated that both length and location are useful prognostic factors, and short strictures located in the large bowel or at the site of prior anastomosis are likely to be most amendable to endoscopic dilation as compared to complex or lengthy de-novo strictures[107-109]. Within our study at least three of the six perforations during stricture dilation were at ulcerated sites, and at least two of the perforations were in patients with previous stricture dilations. As the alternative to symptomatic strictures is surgical resection or strictureplasty, our results suggest that stricture dilation via BAE can be done in accessible, short-length symptomatic strictures, and it has better performance in anastomotic strictures, but it may need to be avoided in presence of significant CD-related inflammation.

The relative excess risk of endoscopy associated perforations among IBD patients as compared to non-IBD patients has previously been demonstrated, with disease severity and steroid use (a surrogate for disease activity) being two of the strongest predictors for a procedure related perforation[30,110-112]. Within our systematic review, the total rate of perforation with BAE in CD (4.27 per 1000 procedures) when including both diagnostic and therapeutic procedures was nearly 4 times that reported with diagnostic balloon assisted enteroscopy for all indications (1.1 per 1000 procedures), and the significant majority of this risk was seen in therapeutic procedures.

Our results demonstrate that diagnostic BAE is a safe tool in monitoring small bowel disease activity and may have a role in guiding medical treatment to achieve clinical remission and mucosal healing. The rate of perforation with diagnostic BAE in CD (1.55 per 1000) was also similar to that reported with lower endoscopy in IBD patients (1.89 per 1000)[112]. Other modalities have been demonstrated to have a reasonable diagnostic accuracy for assessing small bowel disease activity in CD[22,113-124], but they have several technical and practical limitations that prevent their routine use in clinical practice[48,113,114,121,125-127]. In our pooled analysis, findings from BAE in conjunction with changes in medical therapy resulted in improved clinical and endoscopic disease activity in a substantial majority of patients. Although further prospective studies are needed to understand the positioning of BAE in disease activity assessment and treating to a target of mucosal healing in CD, these data suggest that BAE may be a useful tool for assessing small bowel disease activity and treatment response in CD.

Our study has highlighted several key findings but it also has several limitations. There is an inherent selection bias in patients who undergo BAE that undoubtedly affects our results. The majority of analyzed studies were retrospective with variable objectives, different inclusion criteria, and limited follow-up data. Additionally, the lack of prospective studies comparing BAE to cross-sectional imaging in evaluation of small bowel disease makes evaluating the utility of diagnostic BAE difficult. Lastly, BAE has a high rate of incomplete enteroscopy[64], which likely was not portrayed in our results, as completion rates were not consistently documented. Strengths of our study included the extensive search performed and the large number of patients and procedures analyzed.

Diagnostic BAE in CD has a similar perforation rate as diagnostic BAE in other indications and may help safely guide medical therapy via assessment of mucosal healing. Therapeutic BAE may help avoid surgery in patients with symptomatic strictures, but the rate of perforation with therapeutic procedures is higher and thus providers must exercise caution when utilizing this endoscopic technique. Further efforts should focus on risk stratification of patients to ensure optimal safety and diagnostic yield and further studies are needed to identify patient and stricture characteristics at highest risk for procedure related complications.

**Comments**

***Background***

Crohn’s disease (CD) often affects the small bowel, but conventional upper and lower endoscopy are limited in their evaluation of small bowel disease activity or ability to perform interventions. Balloon assisted enteroscopy (BAE) allows for direct visualization and sampling of the small bowel, however its safety and role in CD remain to be established.

***Research frontiers***

This systematic review reveals that diagnostic BAE in cd has similar perforation rates as diagnostic BAE for all indications, suggesting that BAE is a safe way to evaluate small bowel CD. Further randomized controlled trials are warranted to confirm these findings as well as to identify anatomical characteristics that are at highest risk for procedure related complications.

***Innovations and breakthroughs***

The research demonstrates that BAE has a similar perforation rate in diagnostic evaluation of small bowel CD versus other indications. This systematic review is the most up-to-date overview of this subject matter.

***Applications***

Diagnostic BAE in CD has a similar perforation rate as in other indications, thus it can be safely performed in diagnostic evaluation of small bowel CD.

***Peer-review***

The present manuscript is well written. The efficacy, safety and long-term prognosis of balloon dilation using BAE should be separately shown between patients with small bowel strictures and patients with anastomotic strictures. This should be analyzed in the manuscript.

**REFERENCES**

1 **Loftus EV**. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004; **126**: 1504-1517 [PMID: 15168363]

2 **Louis E**, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. *Gut* 2001; **49**: 777-782 [PMID: 11709511]

3 **Cosnes J**, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. *Inflamm Bowel Dis* 2002; **8**: 244-250 [PMID: 12131607]

4 **Khanna R**, Levesque BG, Bressler B, Zou G, Stitt L, Greenberg GR, Panaccione R, Bitton A, Pare P, Vermeire S, D'Haens GR, MacIntosh DG, Sandborn W, Vandervoort MK, Morris JC, Feagan BG. 1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial. *Gastroenterology*; **146**: S-187 [DOI: 10.1016/S0016-5085(14)60664-8]

5 **Froslie KF**, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology* 2007; **133**: 412-422

6 **Schnitzler F**, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. *Inflamm Bowel Dis* 2009; **15**: 1295-1301 [PMID: 19340881 DOI: 10.1002/ibd.20927]

7 **Rutgeerts P**, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. *Gastrointest Endosc* 2006; **63**: 433-42; quiz 464 [PMID: 16500392 DOI: 10.1016/j.gie.2005.08.011]

8 **Baert F**, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. *Gastroenterology* 2010; **138**: 463-48; quiz 463-48; [PMID: 19818785 DOI: 10.1053/j.gastro.2009.09.056]

9 **Bouguen G**, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2014; **12**: 978-985 [PMID: 24246770 DOI: 10.1016/j.cgh.2013.11.005]

10 **Bouguen G**, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to target: a proposed new paradigm for the management of Crohn's disease. *Clin Gastroenterol Hepatol* 2015; **13**: 1042-50.e2 [PMID: 24036054 DOI: 10.1016/j.cgh.2013.09.006]

11 **Steinhardt HJ**, Loeschke K, Kasper H, Holtermüller KH, Schäfer H. European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. *Digestion* 1985; **31**: 97-108 [PMID: 2860044]

12 **Mekhjian HS**, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. *Gastroenterology* 1979; **77**: 898-906 [PMID: 381094]

13 **Voderholzer WA**, Beinhoelzl J, Rogalla P, Murrer S, Schachschal G, Lochs H, Ortner MA. Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. *Gut* 2005; **54**: 369-373 [PMID: 15710985 DOI: 10.1136/gut.2004.040055]

14 **Travis SP**, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. *Gut* 2006; **55** Suppl 1: i16-i35 [PMID: 16481629 DOI: 10.1136/gut.2005.081950b]

15 **Sandborn WJ**, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. *Gastroenterology* 2002; **122**: 512-530 [PMID: 11832465]

16 **Ajlouni Y**, Iser JH, Gibson PR. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. *J Gastroenterol Hepatol* 2007; **22**: 486-490 [PMID: 17376038 DOI: 10.1111/j.1440-1746.2006.04764.x]

17 **Hassan C**, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: Endoscopic dilatation in Crohn's disease. *Aliment Pharmacol Ther* 2007; **26**: 1457-1464 [PMID: 17903236 DOI: 10.1111/j.1365-2036.2007.03532.x]

18 **Hommes DW**, van Deventer SJ. Endoscopy in inflammatory bowel diseases. *Gastroenterology* 2004; **126**: 1561-1573 [PMID: 15168367]

19 **Kopylov U**, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. *Am J Gastroenterol* 2015; **110**: 1316-1323 [PMID: 26215531 DOI: 10.1038/ajg.2015.221]

20 **Dulai PS**, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. *Gastrointest Endosc* 2015; **82**: 246-255 [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974]

21 **Triester SL**, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. *Am J Gastroenterol* 2006; **101**: 954-964 [PMID: 16696781 DOI: 10.1111/j.1572-0241.2006.00506.x]

22 **Dionisio PM**, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. *Am J Gastroenterol* 2010; **105**: 1240-128; quiz 1249 [PMID: 20029412 DOI: 10.1038/ajg.2009.713]

23 **Tae CH**, Shim KN. Should capsule endoscopy be the first test for every obscure gastrointestinal bleeding? *Clin Endosc* 2014; **47**: 409-414 [PMID: 25324999 DOI: 10.5946/ce.2014.47.5.409]

24 **Cheifetz AS**, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. *Am J Gastroenterol* 2006; **101**: 2218-2222 [PMID: 16848804 DOI: 10.1111/j.1572-0241.2006.00761.x]

25 **Mönkemüller K**, Weigt J, Treiber G, Kolfenbach S, Kahl S, Röcken C, Ebert M, Fry LC, Malfertheiner P. Diagnostic and therapeutic impact of double-balloon enteroscopy. *Endoscopy* 2006; **38**: 67-72 [PMID: 16429357 DOI: 10.1055/s-2005-921190]

26 **Fry LC**, Bellutti M, Neumann H, Malfertheiner P, Monkemuller K. Utility of double-balloon enteroscopy for the evaluation of malabsorption. *Dig Dis* 2008; **26**: 134-139 [PMID: 18431063 DOI: 10.1159/000116771]

27 **Jovanovic I**, Vormbrock K, Zimmermann L, Djuranovic S, Ugljesic M, Malfertheiner P, Fry LC, Mönkemüller K. Therapeutic double-balloon enteroscopy: a binational, three-center experience. *Dig Dis* 2011; **29** Suppl 1: 27-31 [PMID: 22104749 DOI: 10.1159/000331125]

28 **Fan R**, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH. Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. *World J Gastroenterol* 2014; **20**: 14479-14487 [PMID: 25339835 DOI: 10.3748/wjg.v20.i39.14479]

29 **Murphy SJ**, Kornbluth A. Double balloon enteroscopy in Crohn's disease: where are we now and where should we go? *Inflamm Bowel Dis* 2011; **17**: 485-490 [PMID: 20577975 DOI: 10.1002/ibd.21373]

30 **Odagiri H**, Matsui H, Fushimi K, Kaise M, Yasunaga H. Factors associated with perforation related to diagnostic balloon-assisted enteroscopy: analysis of a national inpatient database in Japan. *Endoscopy* 2015; **47**: 143-146 [PMID: 25412096 DOI: 10.1055/s-0034-1390891]

31 **Xin L**, Liao Z, Jiang YP, Li ZS. Indications, detectability, positive findings, total enteroscopy, and complications of diagnostic double-balloon endoscopy: a systematic review of data over the first decade of use. *Gastrointest Endosc* 2011; **74**: 563-570 [PMID: 21620401 DOI: 10.1016/j.gie.2011.03.1239]

32 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 0197-2456(86)90046-2]

33 **Despott EJ**, Gupta A, Burling D, Tripoli E, Konieczko K, Hart A, Fraser C. Effective dilation of small-bowel strictures by double-balloon enteroscopy in patients with symptomatic Crohn's disease (with video). *Gastrointest Endosc* 2009; **70**: 1030-1036 [PMID: 19640518 DOI: 10.1016/j.gie.2009.05.005]

34 **Gill RS**, Kaffes AJ. Small bowel stricture characterization and outcomes of dilatation by double-balloon enteroscopy: a single-centre experience. *Therap Adv Gastroenterol* 2014; **7**: 108-114 [PMID: 24790641 DOI: 10.1177/1756283X13513995]

35 **Halloran BP**, Melmed GY, Jamil LH, Lo SK, Vasiliauskas EA, Mann NK. Double balloon enteroscopy-assisted stricture dilation delays surgery in patients with small bowel crohn's disease. *Gastrointest Endosc* 2013; **(1)**: AB280

36 **Mensink PB**, Aktas H, Zelinkova Z, West RL, Kuipers EJ, van der Woude CJ. Impact of double-balloon enteroscopy findings on the management of Crohn's disease. *Scand J Gastroenterol* 2010; **45**: 483-489 [PMID: 20059403 DOI: 10.3109/00365520903563774]

37 **Morishima K**, Ohmiya N, Nakamura M, Shirai O, Takenaka H, Miyahara R, Watanabe O, Ando T, Kawashima H, Itoh A, Hirooka Y, Niwa Y, Goto H. The evaluation of the postoperative Crohn's jejunoileitis and balloon dilation for the strictures by using double balloon enteroscopy (DBE). *Gastrointest Endosc* 2009; **69**: AB198 [DOI: 10.1016/j.gie.2009.03.433]

38 **Ohmiya N**, Arakawa D, Nakamura M, Honda W, Shirai O, Taguchi A, Itoh A, Hirooka Y, Niwa Y, Maeda O, Ando T, Goto H. Small-bowel obstruction: diagnostic comparison between double-balloon endoscopy and fluoroscopic enteroclysis, and the outcome of enteroscopic treatment. *Gastrointest Endosc* 2009; **69**: 84-93 [PMID: 19111689 DOI: 10.1016/j.gie.2008.04.067]

39 **Pohl J**, May A, Nachbar L, Ell C. Diagnostic and therapeutic yield of push-and-pull enteroscopy for symptomatic small bowel Crohn's disease strictures. *Eur J Gastroenterol Hepatol* 2007; **19**: 529-534 [PMID: 17556897 DOI: 10.1097/MEG.0b013e328012b0d0]

40 **Yamada K**, Ohmiya N, Nagura A, Ishihara M, Ohara K, Ohno E, Kawashima H, Miyahara R, Itoh A, Hirooka Y, Watanabe O, Ando T, Goto H. Usefulness of endoscopic diagnosis of postoperative small-bowel lesions and balloon dilation for strictures in patients with crohn's disease at double-balloon enteroscopy. *Gastrointest Endosc* 2012; **(1)**: AB251 [DOI: 10.1016/j.gie.2012.04.229]

41 **Bartel MJ**, Kroner T, Stark ME, Lukens F. Yield of double balloon enteroscopy for chronic GI symptoms suggestive of crohn's disease with negative colonoscopy. *Gastroenterology* 2014; **(1)**: S-40 [DOI: 10.1016/S0016-5085(14)60141-4]

42 **Jang HJ**, Choi MH, Eun CS, Choi H, Choi KY, Park DI, Park JH, Chang DK, Kim JO, Ko BM, Huh KC, Byeon JS, Choi Kd, Choi JH, Shin SJ, Kae SH, Lee MS. Clinical usefulness of double balloon enteroscopy in suspected Crohn's disease: the KASID multi-center trial. *Hepatogastroenterology* 2014; **61**: 1292-1296 [PMID: 25436299]

43 **Li X**, Chen H, Dai J, Gao Y, Ge Z. Predictive role of capsule endoscopy on the insertion route of double-balloon enteroscopy. *Endoscopy* 2009; **41**: 762-766 [DOI: 10.1055/s-0029-1215009]

44 **May A**, Färber M, Aschmoneit I, Pohl J, Manner H, Lotterer E, Möschler O, Kunz J, Gossner L, Mönkemüller K, Ell C. Prospective multicenter trial comparing push-and-pull enteroscopy with the single- and double-balloon techniques in patients with small-bowel disorders. *Am J Gastroenterol* 2010; **105**: 575-581 [PMID: 20051942 DOI: 10.1038/ajg.2009.712]

45 **Takenaka K**, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Watanabe M. Comparing MR enterocolonography to enteroscopy in Crohn's disease, especially focusing on small intestinal findings [Internet]. *J Crohns Colitis* 2014; **8**: S170-S171

46 **Wiarda BM**, Mensink PBF, Heine DGN, Stolk M, Dees J, Hazenberg H, Stoker J, Van Der Woude CJ, Kuipers EJ. Small bowel Crohn's disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. *Abdom Imaging* 2012; **37**: 397-403 [DOI: 10.1007/s00261-011-9816-8]

47 **Nakano M**, Oka S, Tanaka S, Aoyama T, Watari I, Hayashi R, Miyaki R, Nagai K, Sanomura Y, Yoshida S, Ueno Y, Chayama K. Clinical usefulness of classification by transabdominal ultrasonography for detection of small-bowel stricture. *Scand J Gastroenterol* 2013; **48**: 1041-1047 [PMID: 23906185 DOI: 10.3109/00365521.2013.822546]

48 **Rahman A**, Ross A, Leighton JA, Schembre D, Gerson L, Lo SK, Waxman I, Dye C, Semrad C. Double-balloon enteroscopy in Crohn's disease: findings and impact on management in a multicenter retrospective study. *Gastrointest Endosc* 2015; **82**: 102-107 [PMID: 25840927 DOI: 10.1016/j.gie.2014.12.039]

49 **Bartel MJ**, Stauffer J, Kroner T, Stark ME, Lukens F. Lodged foreign bodies in the small bowel-proceed to surgery or perform double balloon enteroscopy first? *Gastroenterology* 2014; **(1)**: S-1051 [DOI: 10.1016/S0016-5085(14)63830-0]

50 **Bartel MJ**, KroNer T, Stark ME, Lukens F. What is the significance of small bowel strictures diagnosed by double balloon enteroscopy? analysis of a large prospectively collected database. *Gastrointest Endosc* 2014; **(1)**: AB149-AB150 [DOI: 10.1016/j.gie.2014.02.124]

51 **Di Caro S**, May A, Heine DGN, Fini L, Landi B, Petruzziello L, Cellier C, Mulder CJ, Costamagna G, Ell C, Gasbarrini A. The European experience with double-balloon enteroscopy: Indications, methodology, safety, and clinical impact. *Gastrointest Endosc* 2005; **62**: 545-550 [DOI: 10.1016/j.gie.2005.04.029]

52 **Domagk D**, Mensink P, Aktas H, Lenz P, Meister T, Luegering A, Ullerich H, Aabakken L, Heinecke A, Domschke W, Kuipers E, Bretthauer M. Single- vs. double-balloon enteroscopy in small-bowel diagnostics: a randomized multicenter trial. *Endoscopy* 2011; **43**: 472-476 [PMID: 21384320 DOI: 10.1055/s-0030-1256247]

53 **Huang Y**, Shao CH, Leung YK. [Application of double balloon enteroscopy in pediatric patients]. *Zhonghua Er Ke Za Zhi* 2010; **48**: 599-602 [PMID: 21055305]

54 **Jeon SR**, Kim JO, Kim HG, Lee TH, Kim WJ, Ko BM, Cho JY, Lee JS, Lee MS. Double-balloon enteroscopy in Crohn's disease with small bowel involvement: The characteristics and clinical significance [Internet]. *J Crohns Colitis* 2013; **7**: S112-S113

55 **Lakatos PL**, Fuszek P, Horvath HC, Zubek L, Haller P, Papp J. Double-balloon enteroscopy for the diagnosis and treatment of obscure bleeding, inflammatory bowel diseases and polyposis syndromes: we see more but do we know more? *Hepatogastroenterology* 2008; **55**: 133-137 [PMID: 18507092]

56 **Liu W**, Xu C, Zhong J. The diagnostic value of double-balloon enteroscopy in children with small bowel disease: report of 31 cases. *Can J Gastroenterol* 2009; **23**: 635-638 [PMID: 19816629 DOI: 10.1155/2009/281040]

57 **Lurix EG**, Charles RJ, Ukleja A. A tertiary care center experience with double-balloon enteroscopy. *Gastrointest Endosc* 2011; **(1)**: AB464 [DOI: 10.1016/j.gie.2011.03.1110]

58 **Maaser C**, Schmedt A, Bokemeyer M, Kannengiesser K, Ullerich H, Lugering A, Domagk D, Domschke W, Kucharzik T. Long-term efficacy and safety of double balloon enteroscopy prospective and retrospective data from a single center study. *Scand J Gastroenterol* 2010; **45**: 992-999 [DOI: 10.3109/00365521003710182]

59 **Mann NK**, Jamil LH, Lo SK. High completion rates in double balloon enteroscopy (DBE) are possible in a north american patient population. *Gastrointest Endosc* 2012; **(1)**: AB264-AB265 [DOI: 10.1016/j.gie.2012.04.273]

60 **Mann NK**, Jamil LH, Lo SK. Total enteroscopy should be used to validate capsule endoscopy and other imaging technologies of the small intestine. *Gastroenterology* 2014; **(1)**: S-39 [DOI: 10.1016/S0016-5085(14)60137-2]

61 **Manner H**, May A, Pohl J, Farber M, Ell C. Impact of fluoroscopy on oral double-balloon enteroscopy: Results of a randomized trial in 156 patients. *Endoscopy* 2010; **42**: 820-826 [DOI: 10.1055/s-0030-1255727]

62 **Milewski J**, Zuk K, Nasierowska-Guttmejer A, Rydzewska G. Double balloon enteroscopy (DBE) in suspected small-bowel crohn's disease-one center experience. *Gastrointest Endosc* 2013; **(1)**: AB279-AB280 [DOI: 10.1016/j.gie.2013.03.699]

63 **Moreels TG**, Mensink P, Kuipers EJ, Escher JC, Pelckmans PA. Small bowel evaluation by double-balloon enteroscopy in pediatric patients: Results of two university hospital endoscopy units. *Gastrointest Endosc* 2009; **69**: AB172 [DOI: 10.1016/j.gie.2009.03.328]

64 **Moschler O**, May A, Muller MK, Ell C. Complications in and performance of double-balloon enteroscopy (DBE): Results from a large prospective DBE database in Germany. *Endoscopy* 2011; **43**: 484-489 [DOI: 10.1055/s-0030-1256249]

65 **Parker C**, Perowne R, Nylander D, Panter S. Yield of double balloon enteroscopy in the investigation of possible or recurrent Crohn's disease [Internet]. *J Crohns Colitis* 2013; **7**: S54

66 **Pata C**, Akyuz U, Erzin Y, Mercan A. Double-balloon enteroscopy: The diagnosis and management of small bowel diseases. *Turk J Gastroenterol* 2010; **21**: 353-359 [DOI: 10.4318/tjg.2010.0120]

67 **Peng J**, Leng AM, Wu RY, Yang HX, Yuan WJ, Zou YY, Zhang GY. [The diagnostic value of double-balloon enteroscopy in 67 cases with obscure abdominal pain]. *Zhonghua Nei Ke Za Zhi* 2009; **48**: 111-113 [PMID: 19549463]

68 **Qing C**, An H. Clinical analysis of 93 case double-ballon enteroscopy in smal bowel diseases. *J Gastroenterol Hepatol* 2013; **28**: 723 [DOI: 10.1111/jgh.12363\_3]

69 **Schulz C**, Mönkemüller K, Salheiser M, Bellutti M, Schütte K, Malfertheiner P. Double-balloon enteroscopy in the diagnosis of suspected isolated Crohn's disease of the small bowel. *Dig Endosc* 2014; **26**: 236-242 [PMID: 23855454 DOI: 10.1111/den.12142]

70 **Seiderer J**, Herrmann K, Diepolder H, Schoenberg SO, Wagner AC, Göke B, Ochsenkühn T, Schäfer C. Double-balloon enteroscopy versus magnetic resonance enteroclysis in diagnosing suspected small-bowel Crohn's disease: results of a pilot study. *Scand J Gastroenterol* 2007; **42**: 1376-1385 [PMID: 17852865 DOI: 10.1080/00365520701397867]

71 **Shen R**, Sun B, Gong B, Zhang S, Cheng S. Double-balloon enteroscopy in the evaluation of small bowel disorders in pediatric patients. *Dig Endosc* 2012; **24**: 87-92 [DOI: 10.1111/j.1443-1661.2011.01175.x]

72 **Shi H**, Ren J, Dong W. Double-balloon enteroscopy in the diagnosis and management of small-bowel diseases. *Hepatogastroenterology* 2011; **58**: 477-486 [PMID: 21661416]

73 **Sidhu R**, McAlindon ME, Hardcastle S, Sanders DS. Double balloon enteroscopy in the era of capsule endoscopy: Necessity or luxury? *Gut* 2011; **60**: A253 [DOI: 10.1136/gut.2011.239301.537]

74 **Sun B**, Shen R, Cheng S, Zhang C, Zhong J. The role of double-balloon enteroscopy in diagnosis and management of incomplete small-bowel obstruction. *Endoscopy* 2007; **39**: 511-515 [DOI: 10.1055/s-2007-966376]

75 **Uchida K**, Yoshiyama S, Inoue M, Koike Y, Yasuda H, Fujikawa H, Okita Y, Araki T, Tanaka K, Kusunoki M. Double balloon enteroscopy for pediatric inflammatory bowel disease. *Pediatr Int* 2012; **54**: 806-809 [DOI: 10.1111/j.1442-200X.2012.03661.x]

76 **Urs AN**, Rao PC, Arian Z, Thomson M. Double-balloon enteroscopy in children-a tertiary care experience. *Arch Dis Child* 2011; 96: A15-A16 [DOI: 10.1136/adc.2011.212563.30]

77 **Urs AN**, Martinelli M, Rao P, Thomson MA. Diagnostic and therapeutic utility of double-balloon enteroscopy in children. *J Pediatr Gastroenterol Nutr* 2014; **58**: 204-212 [PMID: 24126830]

78 **Watanabe O**, Ando T, Ishiguro K, Maeda O, Miyake N, Nakamura M, Miyahara R, Ohmiya N, Goto H. Symptoms in patients with Crohn's disease are related to the presence of strictures rather than to that of active ulcers in the small bowel by the examination of double-balloon enteroscopy. *Gastrointest Endosc* 2010; **71**: AB375-AB376 [DOI: 10.1016/j.gie.2010.03.1032]

79 **Westerhoff M**, Pai R, Wilcox R, Semrad C, Noffsinger A, Hart J. Small bowel pathology revealed by double balloon enteroscopy. *Lab Invest* 2009; 89: 152A [DOI: 10.1038/labinvest.2008.138]

80 **Zhang SH**, Xu J, Qing Q, Zhi FC, Bai Y, Xu ZM, Jiang B, Zhang YL, Chen Y. [Value of deep small-bowel endoscopy in the diagnosis of Crohn's disease]. *Nan Fang Yi Ke Da Xue Xue Bao* 2011; **31**: 637-640 [PMID: 21515459]

81 **Zhi FC**, Xiao B, Jiang B, Wan TM, Guo Y, Zhou D, Wang LH, Chen JF, Xie L, Pan DS, Zhou DY. Double-balloon enteroscopy in detecting small intestinal bleeding [Internet]. *Zhonghua Yixue Zazhi* 2005; **118**: 1834-1837

82 **Choi DH**, Jeon SR, Kim JO, Kim HG, Lee TH, Lee WC, Kang BS, Cho JH, Jung Y, Kim WJ, Ko BM, Cho JY, Lee JS, Lee MS. Double-balloon enteroscopy in elderly patients: is it safe and useful? *Intest Res* 2014; **12**: 313-319 [PMID: 25374498 DOI: 10.5217/ir.2014.12.4.313]

83 **Roushan N**, Froutan H, Taslimi R, Kalani M, Ganji A, Darvish Moghaddam S, Farahvash MJ, Khazaeipour Z. Double-balloon Enteroscopy: The results of a new experience in Iran. *Med J Islam Repub Iran* 2014; **28**: 19 [PMID: 25250264]

84 **Chen LH**, Chen WG, Cao HJ, Zhang H, Shan GD, Li L, Zhang BL, Xu CF, Ding KL, Fang Y, Cheng Y, Wu CJ, Xu GQ. Double-balloon enteroscopy for obscure gastrointestinal bleeding: a single center experience in China. *World J Gastroenterol* 2010; **16**: 1655-1659 [PMID: 20355245 doi: 10.3748/WJG.v16.i13.1655]

85 Five year outcomes of Crohn's anastamotic strictures treated with balloon dilatation. *J Crohns Colitis* 2015; **9** Suppl 1: S285 [DOI: 10.1093/ecco-jcc/jju027.530]

86 **Yu LF**, Zhong J, Cheng SD, Tang YH, Miao F. Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease. *J Dig Dis* 2014; **15**: 180-187 [PMID: 24387287 DOI: 10.1111/1751-2980.12127]

87 **Xu N**, Li NE, Cao XL, Wang L, Li XT, Huang LY. The benefit of double-balloon enteroscopy combined with abdominal contrast-enhanced CT examination for diagnosing small-bowel obstruction. *Acta Endoscopica* 2013; **43**: 242-247 [DOI: 10.1007/s10190-013-0342-4]

88 **Watanabe O**, Ando T, Ishiguro K, Maeda O, Miyake N, Nakamura M, Miyahara R, Ohmiya N, Goto H. Recurrence of Ulcers After Small Bowel Resection in Patients With Crohn's Disease: Efficacy of Infliximab As Assessed by Double-Balloon Endoscopy. *Gastrointest Endosc* 2010; **71**: AB376 [DOI: 10.1016/j.gie.2010.03.1033]

89 **Morise K**, Ando T, Watanabe O, Nakamura M, Miyahara R, Maeda O, Ishiguro K, Hirooka Y, Goto H. Clinical utility of a new endoscopic scoring system for Crohn's disease. *World J Gastroenterol* 2015; **21**: 9974-9981 [PMID: 26379402 DOI: 10.3748/wjg.v21.i34.9974]

90 **Akarsu M**, Akkaya Özdinç S, Celtik A, Akpınar H. Diagnostic and therapeutic efficacy of double-balloon endoscopy in patients with small intestinal diseases: single-center experience in 513 procedures. *Turk J Gastroenterol* 2014; **25**: 374-380 [PMID: 25254518 DOI: 10.5152/tjg.2014.5191]

91 **Hirai F**, Beppu T, Takatsu N, Yano Y, Ninomiya K, Ono Y, Hisabe T, Matsui T. Long-term outcome of endoscopic balloon dilation for small bowel strictures in patients with Crohn's disease. *Dig Endosc* 2014; **26**: 545-551 [PMID: 24528293 DOI: 10.1111/den.12236]

92 **Aktas H**, De Ridder L, Haringsma J, Kuipers EJ, Mensink PBF. Complications of single-balloon enteroscopy: A prospective evaluation of 166 procedures. *Endoscopy* 2010; **42**: 365-368 [DOI: 10.1055/s-0029-1243931]

93 **Safatle-Ribeiro AV**, Arraes LR, Ishida RK, Kawaguti FS, Iriya K, Ribeiro U, De Moura EG, Sakai P. Promptly indication of balloon assisted enteroscopy increases the diagnostic yield in patients with current overt obscure gastrointestinal bleeding. *Gastrointest Endosc* 2011; **(1)**: AB458 [DOI: 10.1016/j.gie.2011.03.1087]

94 **Navaneethan U**, Vargo J, Menon KVN, Sanaka M, Tsai CJ. Impact of device-assisted enteroscopy on the diagnosis and management of suspected and established small bowel crohn's disease. *Am J Gastroenterol* 2012; **107**: S124 [DOI: 10.1038/ajg.2012.270]

95 **Aktas H**, Mensink P, Biermann K, Fry LC, Van Der Woude CJ, Malfertheiner P, Monkemuller K. Additional yield of histological sampling in patients with suspected small bowel pathology during balloon assisted enteroscopy. *Gastrointest Endosc* 2010; **71**: AB378 [DOI: 10.1016/j.gie.2010.03.1041]

96 **Arihiro S**, Kato T, Tajiri H. Single-balloon enteroscopy for diagnosis and treatment of small intestine. *Dig Endosc* 2010; **22**: A28 [DOI: 10.1111/j.1443-1661.2010.01003.x]

97 **de Ridder L**, Mensink PB, Lequin MH, Aktas H, de Krijger RR, van der Woude CJ, Escher JC. Single-balloon enteroscopy, magnetic resonance enterography, and abdominal US useful for evaluation of small-bowel disease in children with (suspected) Crohn's disease. *Gastrointest Endosc* 2012; **75**: 87-94 [PMID: 21963066 DOI: 10.1016/j.gie.2011.07.036]

98 **Di Nardo G**, Oliva S, Aloi M, Casciani E, Alessandri C, Di Camillo C, Del Giudice E, Valitutti F, Isoldi S, Cucchiara S. Usefulness of single-balloon enteroscopy in pediatric Crohn's disease. *Dig Liver Dis* 2011; **43**: S405-S406 [DOI: 10.1016/S1590-8658(11)60630-0]

99 **Dutta AK**, Sajith KG, Joseph AJ, Simon EG, Chacko A. Learning curve, diagnostic yield and safety of single balloon enteroscopy. *Trop Gastroenterol* 2012; **33**: 179-184 [PMID: 23600047]

100 **Manno M**, Riccioni ME, Cannizzaro R, Andreoli A, Marmo R, Pennazio M. Diagnostic and therapeutic yield of single balloon enteroscopy in patients with suspected small-bowel disease: Results of the Italian multicentre study. *Dig Liver Dis* 2013; **45**: 211-215 [DOI: 10.1016/j.dld.2012.10.004]

101 **Russo E**, Hoare JM. Single-balloon enteroscopy performed on routine endoscopy lists under conscious sedation. A retrospective report on a single UK centre's experience. *Gastroenterology* 2011; **(1)**: S558 [DOI: 10.1016/S0016-5085(11)62311-1]

102 **Tsujikawa T**, Saitoh Y, Andoh A, Imaeda H, Hata K, Minematsu H, Senoh K, Hayafuji K, Ogawa A, Nakahara T, Sasaki M, Fujiyama Y. Novel single-balloon enteroscopy for diagnosis and treatment of the small intestine: Preliminary experiences. *Endoscopy* 2008; **40**: 11-15 [DOI: 10.1055/s-2007-966976]

103 **Yoshida A**, Takatsuka K, Ueno F, Kobayashi K, Iwabuchi S. Therapeutic single-balloon enteroscopy for small intestinal stenosis may modify outcome of patients with crohn's disease receiving infliximab. *Am J Gastroenterol* 2010; **105**: S421 [DOI: 10.1038/ajg.2010.320-9]

104 **Zhu M**, Tang J, Jin XW, Mao GP, Ning SB, Zhang J, Li YF. Single balloon enteroscopy for diagnosis and treatment of small intestinal diseases. *Shijie Huaren Xiaohua Zazhi* 2013; **21**: 4189-4193 [DOI: 10.11569/wcjd.v21.i36.4189]

105 **Di Nardo G**, Oliva S, Aloi M, Rossi P, Casciani E, Masselli G, Ferrari F, Mallardo S, Stronati L, Cucchiara S. Usefulness of single-balloon enteroscopy in pediatric Crohn's disease. *Gastrointest Endosc* 2012; **75**: 80-86 [DOI: 10.1016/j.gie.2011.06.021]

106 **Morar PS**, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D, Abercrombie J, Ragunath K, Sanders DS, Arnott I, Wilson G, Bloom S, Arebi N. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures. *Aliment Pharmacol Ther* 2015; **42**: 1137-1148 [PMID: 26358739 DOI: 10.1111/apt.13388]

107 **Mueller T**, Rieder B, Bechtner G, Pfeiffer A. The response of Crohn's strictures to endoscopic balloon dilation. *Aliment Pharmacol Ther* 2010; **31**: 634-639 [PMID: 20047581 DOI: 10.1111/j.1365-2036.2009.04225.x]

108 **Endo K**, Takahashi S, Shiga H, Kakuta Y, Kinouchi Y, Shimosegawa T. Short and long-term outcomes of endoscopic balloon dilatation for Crohn's disease strictures. *World J Gastroenterol* 2013; **19**: 86-91 [PMID: 23326167 DOI: 10.3748/wjg.v19.i1.86]

109 **Foster EN**, Quiros JA, Prindiville TP. Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease. *J Clin Gastroenterol* 2008; **42**: 880-885 [PMID: 18645528 DOI: 10.1097/MCG.0b013e3181354440]

110 **Navaneethan U**, Parasa S, Venkatesh PG, Trikudanathan G, Shen B. Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. *J Crohns Colitis* 2011; **5**: 189-195 [PMID: 21575880 DOI: 10.1016/j.crohns.2010.12.005]

111 **Navaneethan U**, Kochhar G, Phull H, Venkatesh PG, Remzi FH, Kiran RP, Shen B. Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. *J Crohns Colitis* 2012; **6**: 470-475 [PMID: 22398061 DOI: 10.1016/j.crohns.2011.10.005]

112 **Mukewar S**, Costedio M, Wu X, Bajaj N, Lopez R, Brzezinski A, Shen B. Severe adverse outcomes of endoscopic perforations in patients with and without IBD. *Inflamm Bowel Dis* 2014; **20**: 2056-2066 [PMID: 25265263 DOI: 10.1097/mib.0000000000000154]

113 **Hall B**, Holleran G, Chin JL, Smith S, Ryan B, Mahmud N, McNamara D. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. *J Crohns Colitis* 2014; **8**: 1601-1609 [PMID: 25257546 DOI: 10.1016/j.crohns.2014.09.005]

114 **Efthymiou A**, Viazis N, Mantzaris G, Papadimitriou N, Tzourmakliotis D, Raptis S, Karamanolis DG. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. *Inflamm Bowel Dis* 2008; **14**: 1542-1547 [PMID: 18521929 DOI: 10.1002/ibd.20509]

115 Small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease. *J Crohns Colitis* 2015; **9** Suppl 1: S178 [DOI: 10.1093/ecco-jcc/jju027.321]

116 **Kopylov U**, Nemeth A, Koulaouzidis A, Makins R, Wild G, Afif W, Bitton A, Johansson GW, Bessissow T, Eliakim R, Toth E, Seidman EG. Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers. *Inflamm Bowel Dis* 2015; **21**: 93-100 [PMID: 25517597 DOI: 10.1097/MIB.0000000000000255]

117 **Sakuraba H**, Ishiguro Y, Hasui K, Hiraga H, Fukuda S, Shibutani K, Takai Y. Prediction of maintained mucosal healing in patients with Crohn's disease under treatment with infliximab using diffusion-weighted magnetic resonance imaging. *Digestion* 2014; **89**: 49-54 [PMID: 24458113 DOI: 10.1159/000356220]

118 **Tielbeek JA**, Löwenberg M, Bipat S, Horsthuis K, Ponsioen CY, D'Haens GR, Stoker J. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn's disease. *Inflamm Bowel Dis* 2013; **19**: 1943-1950 [PMID: 23765176 DOI: 10.1097/MIB.0b013e3182905536]

119 **Ordás I**, Rimola J, Rodríguez S, Paredes JM, Martínez-Pérez MJ, Blanc E, Arévalo JA, Aduna M, Andreu M, Radosevic A, Ramírez-Morros AM, Pinó S, Gallego M, Jauregui-Amezaga A, Ricart E, Panés J. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. *Gastroenterology* 2014; **146**: 374-82.e1 [PMID: 24177375 DOI: 10.1053/j.gastro.2013.10.055]

120 **Van Assche G**, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. *J Crohns Colitis* 2013; **7**: 950-957 [PMID: 23411006 DOI: 10.1016/j.crohns.2013.01.011]

121 **Kani K**, Kato S, Kobayashi T, Yamamoto R, Nagoshi S, Yakabi K. Prospective comparison of computed tomography enterography (CTE) and double balloon enteroscopy (DBE) for the assessment of disease activity and mucosal healing in the small intestinal involvements in patients with crohn's disease. *Gastroenterology* 2013; **(1)**: S424 [DOI: 10.1016/S0016-5085(13)61561-9]

122 **Jensen MD**, Nathan T, Rafaelsen SR, Kjeldsen J. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. *Clin Gastroenterol Hepatol* 2011; **9**: 124-129 [PMID: 21056692 DOI: 10.1016/j.cgh.2010.10.019]

123 **Solem CA**, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. *Gastrointest Endosc* 2008; **68**: 255-266 [PMID: 18513722 DOI: 10.1016/j.gie.2008.02.017]

124 **Jensen MD**, Kjeldsen J, Rafaelsen SR, Nathan T. Diagnostic accuracies of MR enterography and CT enterography in symptomatic Crohn's disease. *Scand J Gastroenterol* 2011; **46**: 1449-1457 [PMID: 21905974 DOI: 10.3109/00365521.2011.613947]

125 **Niv E**, Fishman S, Kachman H, Arnon R, Dotan I. Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. *J Crohns Colitis* 2014; **8**: 1616-1623 [PMID: 24666976 DOI: 10.1016/j.crohns.2014.03.003]

126 **Lim YJ**, Yang CH. Non-steroidal anti-inflammatory drug-induced enteropathy. *Clin Endosc* 2012; **45**: 138-144 [PMID: 22866254 DOI: 10.5946/ce.2012.45.2.138]

127 **Bjarnason I**, Price AB, Zanelli G, Smethurst P, Burke M, Gumpel JM, Levi AJ. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. *Gastroenterology* 1988; **94**: 1070-1074 [PMID: 3345876]

**P-Reviewer:** Kobayashi Y, Lakatos PL, Ogata H, Pinho R **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Specialty Type:** Gastroenterology and Hepatology

**Country of Origin:** United States

**Peer-Review Report Classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Study demographics *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **BAE Studies, *n =* 73**  **Patients, *n =* 1812** | **DBE, *n =* 60**  ***n =* 1509** | **SBE, *n =* 11**  ***n =* 187** |
| Published manuscripts, | 47 (64) | 39 (65) | 8 (72) |
| United States center | 11 (15) | 9 (15) | 0 (0) |
| Prospective | 19 (26) | 14 (23) | 6 (55) |
| Published pre-2010 | 18 (25) | 17 (28) | 1 (10) |
| Crohn’s patients per study | |  |  |
| 5-10 | 26 (36) | 23 (38) | 3 (27) |
| 11-25 | 25 (34) | 20 (33) | 5 (45) |
| > 25 | 22 (30) | 17 (28) | 3 (27) |
| Age, mean ± SD | 42.9 ± 15.4 | 42.4 ± 15.5 | 45.0 ± 15.8 |

Three studies and 116 patients were solely reported as “balloon assisted enteroscopy”; 1 study included both DBE and SBE. DBE: Double balloon enteroscopy; SBE: Single balloon enteroscopy; BAE: balloon assisted enteroscopy.

**Table 2 studies involved international institutions on their experience with balloon assisted enteroscopy**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Published Manuscript** | **2010-present** | **United States** | **Prospective** | **Mean age** | **Patients** | **Procedures** | **Therapeutic** | **Perforations** |
| Akarsu *et al*[90] | X | X |  |  | 47.8 | 39 | 39 | 0 | 0 |
| Aktas *et al*[95] |  | X | X |  | 53 | 58 | 58 | 0 | 0 |
| Aktas *et al*[92] | X | X |  | X | 51 | 31 | 31 | 2 | 0 |
| Arihiro *et al*[96] |  | X |  |  | 56.3 | 32 | 32 | 9 | 1 |
| Bartel *et al*[41] |  | X | X |  | 52.6 | 38 | 38 | 0 | 0 |
| Bartel *et al*[49] |  | X | X |  | 54.3 | 7 | 7 | 7 | 1 |
| Bartel *et al*[50] |  | X | X |  | 62.7 | 15 | 15 | 0 | 0 |
| Chen *et al*[84] | X | X |  |  | 51 | 8 | 8 | 0 | 0 |
| Choi *et al*[82] | X | X |  |  | 43.5 | 7 | 7 | 0 | 0 |
| DeRidder *et al*[97] | X | X |  | X | 15 | 14 | 14 | 0 | 0 |
| Despott *et al*[33] | X |  |  | X | 46.4 | 11 | 13 | 13 | 1 |
| Di Caro *et al*[51] | X |  |  |  | 52 | 7 | 7 | 0 | 0 |
| Di Nardo *et al*[98] | X | X |  | X | 13 | 26 | 26 | 5 | 0 |
| Ding *et al*[85] |  | X |  |  | 39 | 12 | 22 | 22 | 1 |
| Domagk *et al*[52] | X | X |  | X | 52 | 11 | 11 | 0 | 0 |
| Dutta *et al*[99] | X | X |  |  | 42 | 14 | 14 | 0 | 0 |
| Fan *et al*[28] | X | X |  | X | Not reported | 77 | 308 | 0 | 0 |
| Gill *et al*[34] | X | X |  |  | 52.7 | 20 | 20 | 10 | 2 |
| Halloran *et al*[35] |  | X | X |  | 44.8 | 21 | 40 | 40 | 1 |
| Hirai *et al*[91] | X | X |  |  | 36 | 65 | 110 | 110 | 1 |
| Huang *et al*[53] | X |  |  |  | 10 | 7 | 7 | 0 | 0 |
| Jang *et al*[42] | X | X |  |  | 32.7 | 24 | 32 | 0 | 0 |
| Jeon *et al*[54] |  | X |  |  | 36.4 | 30 | 39 | 0 | 0 |
| Lakatos *et al*[55] | X |  |  |  | 51.6 | 6 | 6 | 0 | 0 |
| Li *et al*[43] | X |  |  |  | 49 | 13 | 13 | 0 | 0 |
| Liu *et al*[56] | X |  |  |  | 8.5 | 5 | 5 | 0 | 0 |
| Lurix *et al*[57] |  | X | X |  | 59 | 5 | 5 | 0 | 0 |
| Maaser *et al*[58] | X | X |  | X | 54.9 | 59 | 59 | 0 | 0 |
| Mann *et al*[59] |  | X | X |  | 59 | 9 | 9 | 0 | 0 |
| Mann *et al*[60] |  | X | X |  | 59 | 23 | 23 | 0 | 0 |
| Manner *et al*[61] |  |  |  | X | 56 | 20 | 20 | 0 | 0 |
| Manno *et al*[100] | X | X |  | X | 61 | 11 | 11 | 1 | 0 |
| May *et al*[44] | X | X |  | X | 53 | 9 | 9 | 0 | 0 |
| Mensink *et al*[36] | X | X |  | X | 53 | 50 | 50 | 0 | 0 |
| Milewski *et al*[62] | X |  |  | X | 45 | 75 | 75 | 12 | 0 |
| Moreels *et al*[63] |  | X |  |  | Not reported | 6 | 6 | 0 | 0 |
| Morise *et al*[89] |  |  |  |  | 13 | 76 | 76 | 0 | 0 |
| Morishima *et al*[37] | X | X |  |  | 36 | 17 | 35 | 35 | 0 |
| Moschler *et al*[64] |  |  |  |  | 35.4 | 193 | 193 | 0 | 0 |
| Nakano *et al*[47] | X | X |  | X | 64 | 36 | 36 | 36 | 0 |
| Navaneethan *et al*[94] | X | X |  |  | 56.8 | 49 | 59 | 9 | 1 |
| Ohmiya *et al*[38] | X | X | X |  | 41 | 23 | 23 | 23 | 0 |
| Parker *et al*[65] | X |  |  |  | 48 | 11 | 11 | 0 | 0 |
| Pata *et al*[66] |  | X |  |  | Not reported | 16 | 16 | 4 | 0 |
| Peng *et al*[67] | X | X |  | X | 53 | 15 | 15 | 0 | 0 |
| Pohl *et al*[39] | X |  |  |  | Language1 | 19 | 21 | 21 | 0 |
| Qing *et al*[68] | X |  |  |  | 36 | 7 | 7 | 0 | 0 |
| Rahman *et al*[48] |  | X |  |  | Not reported | 55 | 55 | 3 | 1 |
| Roushan *et al*[83] | X | X | X |  | Not reported | 7 | 7 | 0 | 0 |
| Russo *et al*[101] | X | X |  |  | 47.2 | 6 | 6 | 0 | 0 |
| Safatle *et al*[93] |  | X |  |  | 57 | 9 | 9 | 0 | 0 |
| Schulz *et al*[69] |  | X |  |  | 48.6 | 11 | 11 | 0 | 0 |
| Seiderer *et al*[70] | X | X |  |  | 50.8 | 10 | 10 | 0 | 0 |
| Shen *et al*[71] | X |  |  | X | 33.9 | 8 | 8 | 0 | 0 |
| Shi *et al*[72] | X | X |  |  | 13 | 35 | 35 | 0 | 0 |
| Sidhu *et al*[73] | X | X |  |  | 61.2 | 39 | 39 | 0 | 0 |
| Sun *et al*[74] |  | X |  |  | 52 | 7 | 7 | 0 | 0 |
| Takenaka *et al*[45] | X |  |  | X | 52 | 10 | 10 | 0 | 0 |
| Tsujikawa *et al*[102] | X | X |  | X | 31 | 17 | 17 | 7 | 0 |
| Uchida *et al*[75] | X |  |  |  | 48.9 | 6 | 9 | 1 | 0 |
| Urs *et al*[76] | X | X |  |  | 12.9 | 5 | 5 | 0 | 0 |
| Urs *et al*[77] |  | X |  |  | 12.7 | 7 | 13 | 0 | 0 |
| Watanabe *et al*[88] | X | X |  |  | 10.5 | 10 | 20 | 0 | 0 |
| Watanabe *et al*[78] |  | X |  |  | Not reported | 59 | 60 | 0 | 0 |
| Westerhoff[79] |  | X |  |  | Not reported | 18 | 18 | 0 | 0 |
| Wiarda *et al*[46] |  |  | X |  | Not reported | 18 | 18 | 0 | 0 |
| Xu *et al*[87] | X | X |  | X | 36 | 21 | 21 | 0 | 0 |
| Yamada *et al*[40] | X | X |  |  | Not reported | 46 | 128 | 27 | 0 |
| Yoshida *et al*[103] |  | X |  |  | 37 | 10 | 10 | 5 | 0 |
| Yu *et al*[86] |  | X |  | X | Not reported | 36 | 108 | 0 | 0 |
| Zhang *et al*[80] | X | X |  | X | 31.6 | 5 | 5 | 0 | 0 |
| Zhi *et al*[81] | X | X |  |  | Language1 | 7 | 7 | 0 | 0 |
| Zhu *et al*[104] | X |  |  |  | 36.3 | 23 | 23 | 0 | 0 |

1Language: unable to translate full manuscript, data was extracted from abstract which did not disclose age.

**Table 3 Diagnostic and therapeutic procedures *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Procedures, *n =* 2340** | **Perforations, *n =* 10** | **Rate, (%)** |
| Diagnostic BAE | 1938 (83) | 3 (30) | 0.15 |
| Therapeutic BAE, | 402 (17) | 7 (70) | 1.7 |
| Diagnostic DBE | 1666 (71) | 2 (20) | 0.12 |

BAE: balloon assisted enteroscopy; DBE: double balloon enteroscopy.

**Table 4 Balloon assisted enteroscopy cases with procedure related perforation**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Demographics** | **Site and characteristics of perforation** | **Therapy** | **Procedure** | **Outcome after perforation** |
| Despott *et al*[33] | Long standing CD (> 30 yr) with 5 prior SB resections currently on azathioprine and steroids | 3 jejunal strictures (2 inflammatory, 1 fibrotic) with severe ulcerations at stricture sites | Dilated to maximum of 16.5 mm | DBE - Technically difficult due to adhesion-related angulations and fixation, and strictures were significantly ulcerated | Perforation diagnosed within 8 h, patient had laparotomy and temporary jejunostomy. Patient made full recovery and jejunostomy was reversed. |
| Gill *et al*[34] | Retained video capsule in patient with known CD | Non-obstructing jejunal stricture with mild inflammation and ulceration at the stricture site | Dilated to 15mm | DBE – otherwise not specified | Underwent surgery, outcome otherwise not specified. |
| Gill *et al*[34] | Known CD patient had previously responded well to dilation up to 15mm | Distal obstructing ileal stricture with mild inflammation and ulceration at the stricture site | Dilated to 15mm | DBE – otherwise not specified | Underwent surgery, outcome otherwise not specified. |
| Halloran *et al*[35] | Known CD patient who had undergone prior surgical resection. | Scarred bowel loop adhesion site | Not specified | DBE - Perforation occurred with overtube advancement and straightening of a scarred bowel loop | Outcome not specified. |
| Ding *et al*[85] | Known CD patient | SB stricture, otherwise not specified | Dilation related perforation, otherwise not specified | DBE - Dilation related perforation, otherwise not specified | Perforation diagnosed within 12 hours, patient had laparotomy and resection with ileostomy. |
| Bartel *et al*[49] | Retained video capsule in patient with known CD | SB stricture, otherwise not specified | Not specified | DBE – Otherwise not specified | Emergent surgical intervention, otherwise outcome not specified. |
| Rahman *et al*[48] | Known CD patient | Ulcer at anastomosis site | Not specified | DBE - Perforation directly related to ulcer at anastomosis | Patient made full recovery after surgical resection and primary reanastomosis. |
| Navaneethan *et al*[94] | Known CD patient | Not specified | Not specified | Not specified | Underwent surgery, outcome otherwise not specified |
| Arihiro *et al*[96] | Known CD patient | SB stricture, otherwise not specified | Dilation related perforation, otherwise not specified | SBE - Dilation related perforation, otherwise not specified | Patient improved over time without any surgical intervention. |
| Hirai *et al*[91] | Known CD patient | SB stricture, otherwise not specified | Dilation related perforation, otherwise not specified | DBE - Dilation related perforation, otherwise not specified | Patient had emergency partial ileal resection and made a full recovery. |

CD: Crohn’S disease; SB: Small bowel; DBE: Double balloon enteroscopy;

SBE: Single balloon enteroscopy.



**Figure 1 Studies identified and reasons for exclusion.** VCE: Video capsule endoscopy; SE: Spiral enteroscopy; IBD: Inflammatory bowel disease; BAE: Balloon-assisted enteroscopy; CD: Crohn’S disease.



**Figure 2 Outcome and impact of balloon-assisted enteroscopy in patients with follow-up.**